CLINICAL MANAGEMENT GUIDELINE

Community acquired pneumonia

ICD10: Pneumonia, unspecified organism [J18.9]

Treatment: Anti-methicillin-resistant staphylococci

It is defined as an acute parenchymal infection of the lungs which characterizes with fever >38ºC (>100ºF), productive cough, chest pain, SOB, and signs of parenchymal consolidation.

This first important decision after securing the patient vitals is to determine the treatment setting. To objectively evaluate the admission decision, please follow Pneumonia Severity Index (PSI), or the CURB65 score and SMART-COP for the disease severity and ICU admission. Despite that, evaluating the ability to oral intake, medication adherence, active danger if sent home, mental/cognitive status and socio-economic status and the healthcare service accessibility should be considered.


If the patient required intensive care unit (ICU) admission, or having a necrotizing or cavitary infiltrates or empyema. Empirical therapy for MRSA is recommended pending sputum and/or blood culture results (A-III) 1.

Treatments

Level 1 / 1
pharmacological
Vancomycin
ROUTE
IV
DOSE
15.000 mg
FREQUENCY
Q12hr
pharmacological
linezolid
ROUTE
IV
DOSE
600.000 mg
FREQUENCY
Q12hr

View complete treatment plan

Access complete guideline of Community acquired pneumonia (Adult) now,
with powerful features to assist you for making better clinical management decision

  • Duplicating mechanism of action of effect
  • Weight based dosing
  • Contraindication
  • Renal dosing
  • Interactions to drugs or diseases
  • Hepatic dosing

And more...